Since 2017, numerous CAR-T therapies have reached the marketplace. This has created a CAR-T funding wave as investors and Big Pharma maneuver to get exposure to this trending area of regenerative medicine.
Today, approved CAR-T cell therapies include: - Kymriah (tisagenlecleucel)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Breyanzi (lisocabtagene maraleucel)
- Abecma (idecabtagene vicleucel)
- relma-cel (relmacabtagene autoleucel)
- Carvykti (ciltacabtagene autoleucel)
- NexCAR19 (actalycabtagene autoleucel)
- Yuanruida (inaticabtagene autoleucel)
Worldwide, more than 170 companies are engaged in developing CAR-T products and therapies. These CAR-T therapy companies have developed nearly 970 early and late-stage therapies. These companies have also signed an incredible 98 collaboration deals to progress the development of various CAR-T product candidates. Of these, 33 collaboration deals have disclosed their financial terms, accounting for a total of $21.7 billion in transactions. If an estimate is made for the collaboration deals that have not disclosed their values, the total value of these 98 collaboration deals would be in the range of an astonishing $63 billion.
Over the past decade, CAR-T companies have also attracted venture capital investments worth an incredible $6.7 billion, enabling these companies to invest heavily into their infrastructure and product pipelines.
During the same period, the CAR-T companies managed to raise an impressive $5.8 billion through IPO funding to further strengthen their technology platforms, clinical trial programs, and corporate efforts.
Within this nascent industry, with over 417,801 patent records and 4,024 granted patents, large pharma has increasingly been seeking to enter the CAR-T field by licensing rights from existing patent owners.
Among the financing types analyzed in this report—which include CAR-T industry IPOs, licensing deals, collaborations, strategic partnerships, and M&A deals—M&A deals constitute the largest financial percentage, accounting for an astounding $95.9 billion over the past decade.
For 48 hours only, you can claim it for 50% off. Remember to act fast, because this offer expires soon.
Be Great, The BioInformant Team
p.s. Interested in other market areas, such as MSCs, iPSCs, exosomes, cord blood and tissue, and other areas of regenerative medicine?
|
